Illumina announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023. The orders represent a diverse customer base spanning research and clinical customer segments in nearly 30 countries, across five continents, all seeking to add NovaSeq X – our fastest, most powerful, most sustainable high-throughput sequencer available.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ILMN:
- FTC Orders Illumina (NASDAQ:ILMN) to Unwind $7B Grail Acquisition
- Illumina to appeal FTC decision in federal court
- Illumina ordered to divest cancer detection test maker GRAIL by FTC
- Carl Icahn responds to Illumina ‘obfuscations’ in open letter
- Illumina urges shareholders to withhold votes for Icahn Group director nominees